- A 6-year Prospective, Observational, Multi-Center Post-Marketing Surveillance of the Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Korea. [Multicenter Study]
- JKJ Korean Med Sci 2019 Apr 01; 34(12):e105
- CONCLUSIONS: Tdap administration to Korean subjects ≥ 10 years, including pregnant women, for the prevention of diphtheria, tetanus and pertussis was shown to have a well-tolerated safety profile.
- Combined vaccines for prophylaxis of infectious conditions. [Journal Article]
- ACArtif Cells Nanomed Biotechnol 2019; 47(1):696-705
- In recent years, the application of vaccines shows limitations, including the high number of vaccine administrations and the fear of safety and effectiveness. In this regard, advanced vaccine product…
In recent years, the application of vaccines shows limitations, including the high number of vaccine administrations and the fear of safety and effectiveness. In this regard, advanced vaccine products have been developed, like the combined vaccines, or are under development, such as nucleic acid vaccines (DNA and RNA), polymer-based vaccines, etc. Moreover, the possible use of traditional, like aluminium hydroxide and aluminium phosphate, or innovative adjuvants, like monophosphoryl lipid A, polysaccharides and nanoparticulate system, may further increase vaccine effectiveness. This review article focuses on the combined vaccines, which, especially when they are associated with adjuvants, reduce the dosing frequency, and prolong the duration of action, thus providing better vaccine coverage. Marketed preparations, like Typhim Vi, Peda typh and Boostrix showed better vaccine coverage for diseases like typhoid, tetanus, diphtheria and acellular pertussis. The future aspect for the development of combined vaccines will protect not only against infectious diseases but likely even against various infectious conditions, like pneumonia, meningococcal infection and respiratory syncytial virus infection.
- Vaccines for travelers. [Review]
- MLMed Lett Drugs Ther 2018 Nov 19; 60(1560):185-192
- Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro. [Journal Article]
- VVaccine 2019 01 03; 37(1):80-89
- Current acellular-pertussis (aP) vaccines appear inadequate for long-term pertussis control because of short-lived efficacy and the increasing prevalence of pertactin-negative isolates which may nega…
Current acellular-pertussis (aP) vaccines appear inadequate for long-term pertussis control because of short-lived efficacy and the increasing prevalence of pertactin-negative isolates which may negatively impact vaccine efficacy. In this study, we added fimbriae (FIM)2 and FIM3 protein to licensed 2-, 3- or 5-component aP vaccines (Pentavac®, Boostrix®, Adacel®, respectively) to assess whether an aP vaccine with enhanced FIM content demonstrates enhanced efficacy. Vaccine-induced protection was assessed in an intranasal mouse challenge model. In addition, potential reactogenicity was measured by biomarkers in a human whole blood assay (WBA) in vitro and benchmarked the responses against licensed whole cell pertussis (wP) and aP vaccines including Easyfive®, Pentavac® and Pentacel®. The results show that commercial vaccines demonstrated reduced efficacy against pertactin-negative versus pertactin-positive strains. However, addition of higher amounts of FIM2/3 to aP vaccines reduced lung colonization and increased vaccine efficacy against a pertactin-negative strain in a dose-dependent manner. Improvements in efficacy were similar for FIM2 and FIM3-expressing strains. Increasing the amount of FIM2/3 proteins in aP formulations did not alter vaccine-induced biomarkers of potential reactogenicity including prostaglandin E2, cytokines and chemokines in human newborn cord and adult peripheral blood tested in vitro. These results suggest that increasing the quantity of FIM proteins in current pertussis vaccine formulations may further enhance vaccine efficacy against B. pertussis infection without increasing the reactogenicity of the vaccine.
- Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination and Autism Spectrum Disorder. [Journal Article]
- PedPediatrics 2018; 142(3)
- CONCLUSIONS: Prenatal Tdap vaccination was not associated with an increased ASD risk. We support recommendations to vaccinate pregnant women to protect infants, who are at highest risk of death after pertussis infection.
- Tdap vaccination during pregnancy to protect newborns from pertussis infection. [Journal Article]
- AIAnn Ig 2018 Jul-Aug; 30(4):346-363
- CONCLUSIONS: There is an increasing evidence that supports the safety, immunogenicity and effectiveness of Triaxis® e Boostrix® pertussis vaccination during pregnancy to protect infants before they receive their primary immunisations. In particular, both vaccines showed 90% effectiveness in the reduction of pertussis disease and hospitalization in newborns, with 95% effectiveness in the reduction of deaths. In Italy, the implementation of antenatal vaccination against pertussis is needed to narrow the gap between the recommendation of the PNPV and the prevention strategies actually offered by the public health system. To reach a good level of vaccine coverage, providers' recommendations are critical. Hence, extensive education of vaccine givers and all primary and secondary healthcare professionals who have any contact with pregnant women is needed.
- Expanded table: some vaccines recommended for use in adults. [Journal Article]
- MLMed Lett Drugs Ther 2018 05 07; 60(1546):e82-e85
- Adult immunization. [Journal Article]
- MLMed Lett Drugs Ther 2018 05 07; 60(1546):73-82
- A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. [Randomized Controlled Trial]
- VVaccine 2018 04 19; 36(17):2300-2306
- CONCLUSIONS: Non-inferiority of dTap-IPVB to dTap-IPVR was demonstrated. Both vaccines had a clinically acceptable safety and reactogenicity profile when co-administered with MMRV to children 3-4 years old.
New Search Next
- Effectiveness of maternal pertussis vaccination in preventing infection and disease in infants: The NSW Public Health Network case-control study. [Journal Article]
- VVaccine 2018 03 27; 36(14):1887-1892
- Infants are at the highest risk of severe complications - including death - as a result of pertussis infection. Controlling pertussis in this group has been challenging, particularly in those too you…
Infants are at the highest risk of severe complications - including death - as a result of pertussis infection. Controlling pertussis in this group has been challenging, particularly in those too young to be vaccinated. Following revised national recommendations in March 2015, the state of New South Wales, Australia, introduced a funded maternal vaccination campaign at 28 - 32 weeks of gestation using a 3-component tetanus-diphtheria-acellular pertussis vaccine (dTpa; Boostrix, GSK). This study aimed to assess the effectiveness of maternal vaccination and add to the growing body of evidence for this strategy.